Kissei Over Active Bladder Agent Phase III Fails To Meet Endpoint
This article was originally published in PharmAsia News
Kissei Pharmaceutical announced that preliminary analysis of a Phase III study of KUC-7483 for overactive bladder indicated that the drug did not meet its primary efficacy endpoint
You may also be interested in...
In an open letter to the European Commission, Parliament and Council presidents, more than 400 cosmetics companies and animal-rights groups accuse the European Chemicals Agency of effectively “shredding” the animal testing ban on cosmetics by requiring testing for certain chemicals under REACH.
Pink Sheet reporters and editors look at the UK MHRA’s surprising approval of the Pfizer/BioNTech coronavirus vaccine, as well as the US reaction, and discuss President-elect Joe Biden’s potential US FDA commissioner nominees.
Divesting the heart valve division will allow LivaNova to focus more resources on its neuromodulation, cardiopulmonary and circulatory support businesses.